RayzeBio Revenue and Competitors

Location

#1684

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • RayzeBio's estimated annual revenue is currently $28.1M per year.(i)
  • RayzeBio's estimated revenue per employee is $193,750
  • RayzeBio's total funding is $419M.

Employee Data

  • RayzeBio has 145 Employees.(i)
  • RayzeBio grew their employee count by 48% last year.

RayzeBio's People

NameTitleEmail/Phone
1
SVP, Clinical OperationsReveal Email/Phone
2
ControllerReveal Email/Phone
3
SVP Development & OperationsReveal Email/Phone
4
VP, BiometricsReveal Email/Phone
5
VP, Global Product LeaderReveal Email/Phone
6
Head Program ManagementReveal Email/Phone
7
SVP, Biology & Translational MedicineReveal Email/Phone
8
SVP, Chemistry InnovationReveal Email/Phone
9
SVP Clinical OperationsReveal Email/Phone
10
General CounselReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is RayzeBio?

Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets

keywords:N/A

$419M

Total Funding

145

Number of Employees

$28.1M

Revenue (est)

48%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RayzeBio News

2021-06-16 - RayzeBio Snags $108M for Cancer Drug Efforts

San Diego-based RayzeBio, a pharmaceuticals company which says it is developing targeted radiopharmaceutical drugs for cancer, has raised $108M in its Series C funding. The company said it has now raised a total of $258M. The new funding was led by Venrock Healthcare Capital Partners and also in ...

2021-06-15 - RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer

RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$46.3M145-6%N/A
#2
$29.1M145N/AN/A
#3
$32.7M1459%N/A
#4
$24.1M146N/AN/A
#5
$22.6M146N/AN/A